Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 41,622 shares at $30.50 ($1.3M) on 2024-10-15, disclosed to the SEC on 2024-10-16.
Scheduled sale ($1.3M) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.03 | 6,136 | $184K | 14.6% |
| 2 | $30.03 | 6,136 | $184K | 14.6% |
| 3 | $30.50 | 14,525 | $443K | 35.1% |
| 4 | $30.50 | 14,525 | $443K | 35.1% |
| 5 | $30.93 | 300 | $9K | 0.7% |
| Total | $30.36 avg | 41,622 |
| $1.3M |
| 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |